What are the current recommendations or guidelines for testosterone therapy in postmenopausal women?

Current Recommendations for Testosterone Use in Postmenopausal Women

The only evidence-based indication for testosterone therapy in postmenopausal women is the treatment of hypoactive sexual desire disorder (HSDD) after formal biopsychosocial assessment 1.

Specific Indication

Testosterone therapy should be reserved exclusively for postmenopausal women diagnosed with HSDD—defined as persistent absence of sexual fantasies, thoughts, desire, or receptivity to sexual activity that causes personal distress. This diagnosis must be made after comprehensive evaluation that excludes modifiable factors such as:

• Relationship problems
• Mental health disorders (depression, anxiety)
• Physical illness
• Medication side effects
• Interpersonal difficulties
• Cultural or religious conflicts

HSDD must be diagnosed through formal biopsychosocial assessment, not based on testosterone blood levels 1.

What Testosterone Does NOT Treat

The evidence explicitly does NOT support testosterone use for:

• Bone health or osteoporosis prevention 1
• Cognitive function or brain health 2
• Energy or fatigue 2
• Muscle strength or lean body mass 1
• Prevention of breast cancer 1
• General "age-related" symptoms 3

Formulation and Dosing Algorithm

Use transdermal (non-oral) testosterone preparations only 1:

1. Starting dose: Aim for physiologic premenopausal testosterone concentrations
2. Avoid oral testosterone: Associated with adverse lipid profiles and not recommended 1
3. Avoid supraphysiologic preparations: Pellets and injections that produce excessive testosterone levels are explicitly not recommended 1

Practical Prescribing (Given No FDA-Approved Female Formulation)

• Off-label use of male transdermal formulations is reasonable if dosed to maintain physiologic female range 1
• Compounded "bioidentical" preparations cannot be recommended due to lack of efficacy and safety data, unless no approved alternative exists 1
• If compounding is necessary, ensure pharmacy compliance with Good Manufacturing Practice standards 1

Monitoring Protocol

Baseline: Measure total testosterone before starting therapy 1

Follow-up schedule:

• Repeat testosterone level at 3-6 weeks after initiation 1
• Monitor testosterone levels every 6 months to screen for overuse and assess for signs of androgen excess 1
• Discontinue if no benefit by 6 months 1

Safety Profile and Limitations

Short-term safety (up to 24 months) 1:

• No serious adverse events when using physiologic doses
• Mild increases in acne and facial/body hair growth possible
• No increase in alopecia, clitoromegaly, or voice changes
• No adverse effects on blood pressure, glucose, or HbA1c
• No increase in mammographic breast density
• No short-term impact on breast cancer risk

Critical Safety Caveats

Long-term safety beyond 24 months is unknown 1. This is a major limitation requiring informed consent discussion.

Populations excluded from trials 1:

• Women with high cardiometabolic disease risk
• Women with prior breast cancer (use caution in hormone-sensitive breast cancer)
• Most trial participants were taking concurrent estrogen therapy

Therefore, safety recommendations cannot be generalized to higher-risk populations.

Cardiovascular concerns 1:

• Non-oral testosterone shows no adverse lipid effects short-term
• Nonsignificant trend toward deep venous thrombosis noted
• Insufficient data on myocardial infarction or death risk

Treatment Approach Algorithm

1. Diagnose HSDD through biopsychosocial assessment (not testosterone levels)
2. Address modifiable factors first: relationship therapy, mental health treatment, medication adjustments
3. Consider multimodal treatment: Combine pharmacologic therapy with psychotherapy as appropriate 1
4. Obtain informed consent: Discuss off-label use, limited long-term safety data, and expected modest benefit
5. Measure baseline testosterone
6. Initiate transdermal testosterone at physiologic doses
7. Recheck testosterone at 3-6 weeks, adjust dose to maintain premenopausal female range
8. Assess clinical response and monitor for androgen excess every 6 months
9. Stop if no benefit by 6 months

Expected Benefit

When effective, testosterone therapy produces modest improvements: approximately one additional satisfying sexual event per month above placebo, with increases in desire, arousal, orgasmic function, pleasure, and responsiveness, plus reduction in sexual distress 1.

Common Pitfalls to Avoid

• Do not use testosterone levels to diagnose HSDD—no cutoff differentiates women with and without sexual dysfunction 1
• Do not prescribe for general menopausal symptoms, fatigue, or cognitive complaints—no evidence supports this
• Do not use pellets or injections—these create supraphysiologic levels
• Do not continue beyond 6 months without clinical benefit
• Do not prescribe to women with active breast cancer without extreme caution